Filters close
Newswise:Video Embedded why-a-targeted-therapy-is-better-than-immunotherapy-for-some-patients-with-inoperable-non-small-cell-lung-cancer
VIDEO
Released: 31-Jan-2024 7:05 PM EST
Why a Targeted Therapy Is Better Than Immunotherapy For Some Patients With Inoperable Non-Small Cell Lung Cancer
Yale Cancer Center/Smilow Cancer Hospital

Non-small cell lung cancer (NSCLC), with an epidermal growth factor receptor (EGFR) mutation, tends not to respond well to immunotherapy treatments, including durvalumab. However, Yale Cancer Center (YCC) researchers recently reported in the Journal of Thoracic Oncology that the targeted therapy osimertinib, when administered after chemotherapy and radiation, is associated with significantly improved progression-free survival (living without the cancer worsening).

Newswise:Video Embedded novel-immunotherapy-selectively-targets-malignant-t-cells
VIDEO
Released: 24-Jan-2024 3:05 PM EST
Novel Immunotherapy Selectively Targets Malignant T Cells
Yale Cancer Center/Smilow Cancer Hospital

One major hurdle in the development of safe and effective immunotherapies has been the risk of depleting healthy T cells during CAR-T treatment that seeks out and kills cancerous T-cells. In a new study published in Nature Communications, Yale Cancer Center researchers have developed a novel CAR-T cell therapy designed to efficiently kill cancerous T cells while leaving most healthy cells intact.

Released: 19-Jan-2024 4:05 PM EST
Leading Gastrointestinal and Genitourinary Cancer Conferences to Feature Yale Cancer Center Researchers
Yale Cancer Center/Smilow Cancer Hospital

Yale Cancer Center researchers at Yale School of Medicine will present new cancer research at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium as well as the ASCO Genitourinary Cancers Symposium this month.

Newswise: Immunotherapy for metastatic cancer on the rise, even near end of life
Released: 4-Jan-2024 12:05 PM EST
Immunotherapy for metastatic cancer on the rise, even near end of life
Yale Cancer Center/Smilow Cancer Hospital

A new study led by Yale Cancer Center researchers at Yale School of Medicine found that while the initiation of immunotherapy near the end of life has increased over time, a closer look at the benefit and value of these therapies in patients with advanced-stage disease is needed.

Newswise: Study: Patient’s Genetic Characteristics May Help Differentiate HER2-Low Advanced Breast Cancers and Guide Treatment Selection
Released: 6-Dec-2023 7:05 PM EST
Study: Patient’s Genetic Characteristics May Help Differentiate HER2-Low Advanced Breast Cancers and Guide Treatment Selection
Yale Cancer Center/Smilow Cancer Hospital

The targeted therapy trastuzumab deruxtecan (T-Dxd), an antibody drug conjugate, is now an approved treatment of HER2-low advanced breast cancers. In a new study led by Yale Cancer Center researchers at Yale School of Medicine, their findings revealed important differences in the genetic makeup of HER2-low advanced breast cancers — a discovery that could lead to better treatment options for patients.

Newswise: New Research Sheds Light on Equitable Treatment Options for Pediatric Patients with Sickle Cell Disease
Released: 6-Dec-2023 12:05 PM EST
New Research Sheds Light on Equitable Treatment Options for Pediatric Patients with Sickle Cell Disease
Yale Cancer Center/Smilow Cancer Hospital

Patients with sickle cell disease (SCD) often face a reduced quality of life and a lower life expectancy. Allotransplantation, the first treatment for SCD with curative potential, comes with risks, including transplant-related mortality. Gene therapy, once approved for SCD, could also offer a lifelong cure without the risk associated with allotransplantation.

Newswise: Study: New Biomarker Tool Helps Select Targeted Therapies to Treat Metastatic Breast Cancers
Released: 4-Dec-2023 3:05 PM EST
Study: New Biomarker Tool Helps Select Targeted Therapies to Treat Metastatic Breast Cancers
Yale Cancer Center/Smilow Cancer Hospital

Two antibody drug conjugates (ADCs), trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG), were approved by the FDA to treat metastatic breast cancers. ADCs are a type of targeted therapy that release cancer drugs to specific tumor cells. The efficacy of T-DXd and SG depends on target expression and the best method for measuring that expression is still not known.

Newswise: Promising Phase III Results Give Hope to Patients with Myelodysplastic Syndromes
Released: 4-Dec-2023 9:30 AM EST
Promising Phase III Results Give Hope to Patients with Myelodysplastic Syndromes
Yale Cancer Center/Smilow Cancer Hospital

Based on the results from this phase III trial, Yale Cancer Center expert Dr. Amer Zeidan says imetelstat, a first-in-class telomerase inhibitor, leads to durable red blood cell transfusion independence and a significant improvement in anemia in heavily transfused lower risk MDS patients.

Newswise: Yale Cancer Center Experts Present New Research at Leading Breast Cancer Symposium
Released: 29-Nov-2023 10:05 AM EST
Yale Cancer Center Experts Present New Research at Leading Breast Cancer Symposium
Yale Cancer Center/Smilow Cancer Hospital

Yale Cancer Center researchers at Yale School of Medicine will present new research at the 46th annual San Antonio Breast Cancer Symposium (SABCS) from December 5 to 9. The international symposium provides leading-edge breast cancer information on prevention, etiology, diagnosis, and therapy as well as experimental biology. This year’s symposium, at the Henry B.

Newswise: Yale Cancer Center Experts Present New Research at Hematology Annual Meeting
Released: 28-Nov-2023 4:05 PM EST
Yale Cancer Center Experts Present New Research at Hematology Annual Meeting
Yale Cancer Center/Smilow Cancer Hospital

Physicians and scientists from Yale Cancer Center, part of Yale School of Medicine, will present new research at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, Calif., from December 9 to 12. This year’s ASH meeting will include oral and poster presentations, workshops, and educational sessions for hematology professionals.

Newswise: Nanoparticles Deliver Treatment Directly to Tumors of Deadly Brain Cancer
Released: 1-Nov-2023 4:05 PM EDT
Nanoparticles Deliver Treatment Directly to Tumors of Deadly Brain Cancer
Yale Cancer Center/Smilow Cancer Hospital

Using nanoparticles administered directly into the cerebrospinal fluid (CSF), a research team has developed a treatment that may overcome significant challenges in treating a particularly deadly brain cancer.

Newswise: Yale Cancer Center Experts Present New Research at Leading European Oncology Conference
Released: 17-Oct-2023 3:05 PM EDT
Yale Cancer Center Experts Present New Research at Leading European Oncology Conference
Yale Cancer Center/Smilow Cancer Hospital

Yale Cancer Center researchers at Yale School of Medicine will present new cancer research at the European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, October 20 to 24. The annual meeting brings together clinicians, researchers, and patient advocates from all over the world. At ESMO 2023, oncologists will discuss new data and report updates on ongoing studies.

Newswise: HPV Discovery Yields Breakthrough in Understanding Protein Activity
Released: 11-Oct-2023 2:05 PM EDT
HPV Discovery Yields Breakthrough in Understanding Protein Activity
Yale Cancer Center/Smilow Cancer Hospital

A new study led by Yale scientists shows that the activity of a portion of a human papillomavirus (HPV) protein does not depend on its amino acid sequence or composition.

Newswise: A promising treatment on the horizon for cancer-related fatigue
Released: 3-Oct-2023 11:05 AM EDT
A promising treatment on the horizon for cancer-related fatigue
Yale Cancer Center/Smilow Cancer Hospital

Cancer-related fatigue (CRF) is a debilitating yet all-too-common condition, which can severely affect quality of life for patients undergoing treatment. For those struggling with CRF, there have been no effective pharmaceutical treatments for the constellation of symptoms that together define the syndrome.

Newswise: New Yale Cancer Center Research Highlighted at Top Radiation Oncology Conference
Released: 29-Sep-2023 3:05 PM EDT
New Yale Cancer Center Research Highlighted at Top Radiation Oncology Conference
Yale Cancer Center/Smilow Cancer Hospital

Yale Cancer Center physicians, scientists, and trainees from Yale School of Medicine present new findings at the 65th annual American Society for Radiation Oncology (ASTRO) meeting from October 1-4 in San Diego, Calif.

Newswise: Asher Marks, MD, in honor of Childhood Cancer Awareness Month
Released: 28-Sep-2023 5:05 PM EDT
Asher Marks, MD, in honor of Childhood Cancer Awareness Month
Yale Cancer Center/Smilow Cancer Hospital

What are some of the biggest challenges you face in caring for cancers in children? The biggest challenges are around supporting the parents. For the most part, children are resilient and upbeat.

Newswise: Study Reveals Colon Tumor Location Matters for Metastatic Disease
Released: 19-Sep-2023 4:05 PM EDT
Study Reveals Colon Tumor Location Matters for Metastatic Disease
Yale Cancer Center/Smilow Cancer Hospital

Colon cancers that spread to the liver may be substantially different depending on the location of where cancerous cells originate, according to new research. The study led by Yale Cancer Center researchers at Yale School of Medicine and Yale School of Public Health provides insight into the unique biology of right-sided and left-sided tumors, which may impact treatment options and patient outcomes.

Newswise: Courtney Gibson, MD, MS, FACS, in honor of Thyroid Cancer Awareness Month
Released: 18-Sep-2023 11:05 AM EDT
Courtney Gibson, MD, MS, FACS, in honor of Thyroid Cancer Awareness Month
Yale Cancer Center/Smilow Cancer Hospital

What advances have made the biggest impact in the treatment of patients with thyroid cancer over the last five years, and what is the outlook for thyroid cancer in the next five years? Molecular testing (MT) to examine somatic changes has become an important adjunct in the diagnosis and treatment of many cancers.

Newswise: Michael E. Karellas, MD, FACS, in honor of Prostate Cancer Awareness Month
Released: 18-Sep-2023 11:05 AM EDT
Michael E. Karellas, MD, FACS, in honor of Prostate Cancer Awareness Month
Yale Cancer Center/Smilow Cancer Hospital

Prostate screening is a critical part of early diagnosis. How would you encourage a man reading this to see his doctor to begin prostate screenings? The decision to screen for prostate cancer is highly individualized, considering each man’s personal risk, race, as well as other potential health conditions.

Newswise: Francine Foss, MD, in honor of Blood Cancer Awareness Month
Released: 18-Sep-2023 11:05 AM EDT
Francine Foss, MD, in honor of Blood Cancer Awareness Month
Yale Cancer Center/Smilow Cancer Hospital

As we honor lymphoma awareness month, what do you want our patients and families to pause and remember?Lymphoma is a disease which can strike any one of us, young and old, at any time.

Newswise: AI more accurately identifies patients with advanced lung cancer that respond to immunotherapy and helps doctors select treatments
Released: 8-Sep-2023 1:05 PM EDT
AI more accurately identifies patients with advanced lung cancer that respond to immunotherapy and helps doctors select treatments
Yale Cancer Center/Smilow Cancer Hospital

Treatment planning for lung cancer can often be complex due to variations in assessing immune biomarkers. In a new study, Yale Cancer Center researchers at Yale School of Medicine used artificial intelligence (AI) tools and digital pathology to improve the accuracy of this process.

Newswise: New immunotherapy treatment brings hope to patients with advanced non-small cell lung cancer
Released: 8-Sep-2023 1:05 PM EDT
New immunotherapy treatment brings hope to patients with advanced non-small cell lung cancer
Yale Cancer Center/Smilow Cancer Hospital

Although immunotherapies have shown promise in treating non-small cell lung cancer (NSCLC), many patients still do not respond well, and those who do may eventually develop resistance.

Newswise: Study: Diet, Exercise Improve Outcomes of Chemotherapy for Women with Breast Cancer
Released: 7-Sep-2023 7:05 PM EDT
Study: Diet, Exercise Improve Outcomes of Chemotherapy for Women with Breast Cancer
Yale Cancer Center/Smilow Cancer Hospital

A new Yale Cancer Center study finds a targeted diet and exercise intervention could improve outcomes for women undergoing chemotherapy for breast cancer.

Newswise: Breakthrough Targeted Therapy Approach for Non-Small Cell Lung Cancer Helps Patients With a Genetic Mutation Live Longer
Released: 7-Sep-2023 4:05 PM EDT
Breakthrough Targeted Therapy Approach for Non-Small Cell Lung Cancer Helps Patients With a Genetic Mutation Live Longer
Yale Cancer Center/Smilow Cancer Hospital

The immunotherapy drug, durvalumab, has been the standard of care for patients with stage III non-small cell lung cancer(NSCLC) to improve survival, when prescribed after chemotherapy and radiation therapy.

Newswise: New international study shows promise of immunotherapy treatment for patients with penile cancer
Released: 11-Aug-2023 11:45 AM EDT
New international study shows promise of immunotherapy treatment for patients with penile cancer
Yale Cancer Center/Smilow Cancer Hospital

Penile squamous cell carcinoma is a rare form of penile cancer with limited treatment options. An international study led by Yale Cancer Center researchers at Yale School of Medicine finds that the use of immune checkpoint inhibitors (ICIs) offers promising clinical benefits for some patients with advanced penile squamous cell carcinoma.

Newswise: New Yale Study Suggests Breast Cancer Screening for Older Women Carries Risks
Released: 8-Aug-2023 10:00 AM EDT
New Yale Study Suggests Breast Cancer Screening for Older Women Carries Risks
Yale Cancer Center/Smilow Cancer Hospital

Breast cancer screening for women over 70 is not without risks, according to new research from Yale School of Medicine’s COPPER Center. Although some guidelines recommend continuing screening for older women, a new study emphasizes the importance of assessing potential harms associated with testing, such as overdiagnosis, which, researchers say, can negatively affect quality of life.

Newswise: New Yale Study Shows Aerobic Exercise Relieves Pain for Ovarian Cancer Survivors
Released: 7-Aug-2023 11:30 AM EDT
New Yale Study Shows Aerobic Exercise Relieves Pain for Ovarian Cancer Survivors
Yale Cancer Center/Smilow Cancer Hospital

One common side effect of treatment for ovarian cancer is chemotherapy-induced peripheral neuropathy (CIPN), which can damage peripheral nerves, causing severe pain and numbness. The effects can last for months – or even years — after completing chemotherapy. Currently, there is only one treatment with limited efficacy for CIPN.

Newswise: Researchers Find a Vulnerability in Lung Cancers Resistant to Targeted Therapies
Released: 3-Aug-2023 11:20 AM EDT
Researchers Find a Vulnerability in Lung Cancers Resistant to Targeted Therapies
Yale Cancer Center/Smilow Cancer Hospital

Targeted therapies have revolutionized cancer treatment and the field of oncology. The FDA has approved over 70 targeted therapies for various cancer types, including lung cancer. Epidermal growth factor receptor (EGFR) mutations are found in a significant proportion of lung adenocarcinomas, and the use of tyrosine kinase inhibitors (TKIs) such as osimertinib, have improved patient outcomes.

Newswise: Smilow Cancer Hospital Recognized Among the Nation’s Best for Cancer Care 2023-2024
Released: 2-Aug-2023 2:05 PM EDT
Smilow Cancer Hospital Recognized Among the Nation’s Best for Cancer Care 2023-2024
Yale Cancer Center/Smilow Cancer Hospital

Smilow Cancer Hospital at Yale New Haven is ranked as one of the highest hospitals for cancer care in the country by U.S. News & World Report. This year, Smilow Cancer Hospital at Yale New Haven is listed in the top 50 in the nation and is number 1 in Connecticut. "We are proud to be recognized as one of the leading cancer hospitals in our country,” said Eric Winer, MD, Director of Yale Cancer Center and Physician-in-Chief of Smilow Cancer Hospital.

Newswise: Researchers develop a new way to classify HPV-associated head and neck cancers
Released: 31-Jul-2023 3:05 PM EDT
Researchers develop a new way to classify HPV-associated head and neck cancers
Yale Cancer Center/Smilow Cancer Hospital

Human papillomavirus (HPV) has been linked to a significant increase in cancers of the throat and tonsils over the past few decades; this is projected to become the most common form of head and neck cancer by 2030. But a major limitation to reducing treatment intensity is the inability to correctly identify the patients whose HPV-related cancers will be the most responsive to treatment.

Newswise: Yale Scientists Identify Immune Cells Critical for Immunologic Memory for Melanoma
Released: 27-Jul-2023 12:30 PM EDT
Yale Scientists Identify Immune Cells Critical for Immunologic Memory for Melanoma
Yale Cancer Center/Smilow Cancer Hospital

Immune-checkpoint inhibitors have become the standard of care for patients with advanced melanoma to improve survival, but only some patients respond to this immunotherapy and have long-term benefits. The lack of a long-lasting response, researchers say, is related to failure of antitumor immunologic memory. Treatment options for advanced melanoma are limited for patients who do not respond to this type of therapy.

Newswise: Yale Scientists Develop a New Approach to Strengthen CAR-T Cell Therapy
Released: 27-Jul-2023 11:55 AM EDT
Yale Scientists Develop a New Approach to Strengthen CAR-T Cell Therapy
Yale Cancer Center/Smilow Cancer Hospital

Chimeric antigen receptor (CAR)-T cells are a powerful, new form of cancer therapy that are being studied to treat blood cancers. Using a new approach, Yale Cancer Center researchers at Yale School of Medicine found a new way to substantially improve the effectiveness of CAR-T cell therapy. The new study was published in Nature Immunology on July 27.

Newswise: Combination Cancer Therapies Can Shrink Tumors and Improve Survival Outcomes for Patients with Advanced Non-Small Cell Lung Cancer
Released: 13-Jul-2023 11:00 AM EDT
Combination Cancer Therapies Can Shrink Tumors and Improve Survival Outcomes for Patients with Advanced Non-Small Cell Lung Cancer
Yale Cancer Center/Smilow Cancer Hospital

While pembrolizumab is an approved treatment for patients with stage III non-small cell lung cancer (NSCLC), only some patients respond to this therapy. Treatment failure, researchers say, is often caused by differences in the tumor microenvironment.

Newswise: Eliminating Extra Chromosomes in Cancer Cells Prevent Tumor Growth
Released: 6-Jul-2023 3:05 PM EDT
Eliminating Extra Chromosomes in Cancer Cells Prevent Tumor Growth
Yale Cancer Center/Smilow Cancer Hospital

Cancer cells with extra chromosomes depend on those chromosomes for tumor growth, a new Yale study reveals, and eliminating them prevents the cells from forming tumors. The findings, said the researchers, suggest that selectively targeting extra chromosomes may offer a new route for treating cancer. The study was published July 6 in the journal Science.

Newswise: Pancreatic Cancer Risk Lower if Pancreatic Cysts Remain Stable for Five Years
Released: 29-Jun-2023 4:05 PM EDT
Pancreatic Cancer Risk Lower if Pancreatic Cysts Remain Stable for Five Years
Yale Cancer Center/Smilow Cancer Hospital

Low-risk branch duct intraductal papillary mucinous neoplasms (IPMN) are the most common precancerous form of mucinous pancreatic cysts and once identified require regular surveillance imaging. But consensus is still forming around how long that watchful period should last.

Newswise: Study hints at how cancer immunotherapy can be safer
Released: 23-Jun-2023 9:25 AM EDT
Study hints at how cancer immunotherapy can be safer
Yale Cancer Center/Smilow Cancer Hospital

Cancer immunotherapy has revolutionized treatment of many forms of cancer by unleashing the immune system response against tumors. Immunotherapies that block checkpoint receptors like PD-1, proteins that limit the capacity of T cells to attack tumors, have become the choice for the treatment of numerous types of solid cancer.

Newswise: Harnessing the power of healthy cells to suppress skin cancer formation
Released: 23-Jun-2023 9:20 AM EDT
Harnessing the power of healthy cells to suppress skin cancer formation
Yale Cancer Center/Smilow Cancer Hospital

Healthy human skin is a mosaic-like collection of both normal and mutation-bearing cells. As people age, a growing number of these cells accumulate more and more mutations including those that can cause cancer. Eventually these mutant cells, which are fueled by environmental insults such as high sun exposure, gradually outcompete the healthy cells, making individuals increasingly susceptible to skin cancers.

Newswise: Early Exposure to Medicine Inspired Committed Careers
Released: 8-Jun-2023 8:05 AM EDT
Early Exposure to Medicine Inspired Committed Careers
Yale Cancer Center/Smilow Cancer Hospital

By their early 20s, two of Yale’s most prominent cancer experts had each been immersed in healthcare battles for many years. Few people would have been surprised if they chose careers outside of healthcare. Instead, Drs. Eric Winer and Patricia LoRusso chose to pursue cancer care and research as their work. Both are now leaders of two of the country’s most prestigious organizations for cancer professionals.

Newswise: Study Shows Osimertinib Improves Survival Following Surgery for Non-Small Cell Lung Cancer
Released: 7-Jun-2023 5:20 PM EDT
Study Shows Osimertinib Improves Survival Following Surgery for Non-Small Cell Lung Cancer
Yale Cancer Center/Smilow Cancer Hospital

A new study led by Yale Cancer Center shows improved rates of survival and reduced risk of recurrence in patients with non-small cell lung cancer taking osimertinib (TAGRISSO), a targeted therapy, following surgery. Non-small cell lung cancer (NSCLC), the most common type of lung cancer, tends to recur when diagnosed at advanced stages, which makes treatment challenging.

Newswise: New findings reveal impact of changing environment for patients with cancer prescribed opioids
Released: 31-May-2023 7:05 AM EDT
New findings reveal impact of changing environment for patients with cancer prescribed opioids
Yale Cancer Center/Smilow Cancer Hospital

In response to the opioid epidemic in the United States, interventions to prevent over-prescribing and misuse of opioids were enacted at institutional, state, and federal levels. To assess how changes in the prescribing landscape affected patients, a research team from the Yale COPPER Center examined the rates of both new and persistent opioid prescribing in patients with cancer as well as in patients without cancer, utilizing data from SEER-Medicare.

Newswise: Yale Cancer Center and Smilow Cancer Hospital Physicians and Scientists Presenting Latest Advances at 2023 ASCO Annual Meeting
Released: 18-May-2023 12:50 PM EDT
Yale Cancer Center and Smilow Cancer Hospital Physicians and Scientists Presenting Latest Advances at 2023 ASCO Annual Meeting
Yale Cancer Center/Smilow Cancer Hospital

Yale Cancer Center and Smilow Cancer Hospital scientists and clinicians will present new research at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO), June 2nd to June 6th at McCormick Place in Chicago, Illinois. This year’s scientific program will feature more than 2,900 abstracts, covering all major diseases and research areas, including breast, lung, head and neck, gynecological, prostate, and gastric cancers.

Newswise: New Yale-led study identifies bereaved parents’ medical priorities for children with advanced cancer
Released: 16-May-2023 8:05 AM EDT
New Yale-led study identifies bereaved parents’ medical priorities for children with advanced cancer
Yale Cancer Center/Smilow Cancer Hospital

For families facing the end of life of a loved one with pediatric cancer, robust quality measures to benchmark what parents value most in their child’s medical care do not currently exist. A new study helps identify what parents prioritize for their children with advanced cancer, including alleviating the child’s symptoms and honoring the family’s goals and wishes.

Newswise: HIPEC Surgery Brings Advanced Abdominal Cancer Treatment to Smilow Cancer Hospital
Released: 5-May-2023 9:30 AM EDT
HIPEC Surgery Brings Advanced Abdominal Cancer Treatment to Smilow Cancer Hospital
Yale Cancer Center/Smilow Cancer Hospital

A technique that delivers high doses of heated chemotherapy directly to the abdominal cavity is a promising treatment for certain patients with Stage IV cancer. Hyperthermic intraperitoneal chemotherapy (HIPEC) kills cancer cells in the abdomen remaining after the surgical removal of tumors.

Newswise: New Study Shows Trastuzumab Deruxtecan Improves Survival for Patients with HER2-positive Metastatic Breast Cancer
Released: 3-May-2023 12:00 PM EDT
New Study Shows Trastuzumab Deruxtecan Improves Survival for Patients with HER2-positive Metastatic Breast Cancer
Yale Cancer Center/Smilow Cancer Hospital

A new phase III study has demonstrated the efficacy of trastuzumab deruxtecan (Enhertu) in patients with HER2-positive metastatic breast cancer whose cancers were resistant to previous treatment with trastuzumab emtansine. Both trastuzumab deruxtecan and trastuzumab emtansine are antibody-drug conjugates, a relatively new type of drug that delivers chemotherapy directly to the cancer cell, minimizing damage to normal tissues.

Newswise: Smilow Cancer Hospital Nurses Present New Research at the Annual ONS Congress
Released: 2-May-2023 10:40 AM EDT
Smilow Cancer Hospital Nurses Present New Research at the Annual ONS Congress
Yale Cancer Center/Smilow Cancer Hospital

This week, 18 Smilow Cancer Hospital nurses will present new oncologic research at the 48th Annual Congress of the Oncology Nursing Society in San Antonio, Texas. Their findings will be revealed during poster and oral presentation sessions from April 26th through April 30th. Some of the featured oral presentation topics include “Designing a Novel Educational Program to Decrease Ambulatory Falls with Injury,” “Monoclonal Antibody Education for Non-Oncology RNs,” and “Oncology Advanced Practice Provider Productivity: Measuring and Justifying our Worth.



close
0.5299